Effectiveness of Clozapine on Employment Outcomes in Treatment-Resistant Schizophrenia: A Retrospective Bidirectional Mirror-Image Study
Haruna Matsuzaki,Masakazu Hatano,Miko Iwata,Takeo Saito,Shigeki Yamada
DOI: https://doi.org/10.2147/NDT.S402945
IF: 2.989
2023-03-16
Neuropsychiatric Disease and Treatment
Abstract:Haruna Matsuzaki, 1, &ast Masakazu Hatano, 1, &ast Miko Iwata, 1 Takeo Saito, 2 Shigeki Yamada 1 1 Department of Clinical Pharmacy, Fujita Health University School of Medicine, Toyoake, 470-1192, Japan; 2 Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, 470-1192, Japan &astThese authors contributed equally to this work Correspondence: Masakazu Hatano, Department of Clinical Pharmacy, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake, Toyoake, Aichi, Japan, Tel +81 562932157, Fax +81 562934537, Email Purpose: Clozapine is more effective than other antipsychotics and is the only antipsychotic approved for treatment-resistant schizophrenia. The objective of this study is to reveal the effect of clozapine on employment using a bidirectional mirror-image model. Patients and Methods: This design was a retrospective observational study that investigated the employment status of patients with treatment-resistant schizophrenia based on medical records. The bidirectional mirror-image model consisted of 1) switching from other antipsychotics to clozapine and 2) switching from clozapine to other antipsychotics. The observation period was 1 year for each pre- and post-clozapine initiation and discontinuation. Results: We included 36 patients in the bidirectional mirror-image model. The regular employment plus employment support rate was significantly higher in the clozapine phase than in the other antipsychotic phase in the bidirectional mirror-image model (30.6% vs 11.1%, P = 0.039). The days of regular employment plus employment support were also significantly longer in the clozapine phase (61.3 ± 106.2 vs 24.7 ± 82.7 days, P = 0.032). As per the unidirectional mirror-image model, switching to clozapine resulted in significantly higher regular employment plus employment support rates in the clozapine phase than those in the other antipsychotic phase (33.3% vs 10.0%, P = 0.039). Switching from clozapine to other antipsychotics did not exhibit significant differences in any outcomes. Conclusion: The results suggest that clozapine is superior to other antipsychotics with respect to achieving employment in patients with treatment-resistant schizophrenia. However, biases specific to the mirror-image model need to be considered. Keywords: clozapine, antipsychotic agents, treatment-resistant schizophrenia, observational study, mental health recovery Schizophrenia is a chronic mental disorder affecting approximately 7 per 1000 people in their lifetime. 1 The psychiatric symptoms of schizophrenia are broadly classified into positive symptoms (ie, delusions and hallucinations), negative symptoms (ie, lack of volition and flattening of affect), and cognitive impairment. Although the primary goal of schizophrenia treatment is clinical recovery to improve these psychiatric symptoms, social recovery in terms of employment, education, and independent living is also essential. 2 In Australian studies, rehabilitation model of care focused on social functioning has achieved overall favorable results. However, clinical recovery does not necessarily lead to social recovery, 3,4 and the employment rate for patients with schizophrenia is generally only 10–30%. 5 Previous studies have shown that social recovery is difficult to achieve relative to clinical recovery, and this is recognized as an important clinical issue. 6,7 Additionally, the mean unemployment costs of schizophrenia are estimated to be as high as $1.58 billion (USD) in Japan. 8 These results indicate that the societal burden of schizophrenia is larger than that of other psychiatric disorders, such as depression or anxiety disorders, contrary to its lower prevalence rate. 8 Antipsychotic drugs blocking dopamine D 2 receptor are effective in treating schizophrenia. However, it has been reported that approximately 30% of patients with schizophrenia have treatment-resistant schizophrenia (TRS) that is poorly responsive to antipsychotic drugs. 9 Clozapine is the only antipsychotic approved for TRS and is recommended as a first-line treatment for TRS in major practice guidelines. 10–12 Clozapine has the largest effect size in improving overall psychiatric symptoms compared to that of other antipsychotics and is also superior in preventing relapse. 13,14 Conversely, a meta-analysis has shown that antipsychotic drugs significantly improve social functioning in schizophrenia. However, this study did not include results for clozapine, and its effects are not clear. 15 Furthermore, studies as -Abstract Truncated-
psychiatry,clinical neurology